Compare Illumina, Inc. (ILMN) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Twilio Inc — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while Twilio Inc trades at $195.94 (market cap $31.15B). The key difference: Illumina, Inc. and Twilio Inc are close in size by market cap, and Illumina, Inc. is trading nearer its 52-week high, Twilio Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | TWLO | |
|---|---|---|
Market Cap | $27.94B | $31.15B |
Sector | Health | Technology |
52-Week High | $194.33 | $236.64 |
52-Week Low | $91.00 | $92.44 |
Enterprise Value | $29.33B | $29.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
Twilio (TWLO) trades at $196.22, down 5.11% in the last session, as investors await Q2 2026 earnings on August 6. The stock shows a bullish technical signal with strong moving average support and oversold RSI conditions. Fundamentally, the company has delivered three consecutive earnings beats with revenue growth from $3.8B in 2022 to $5.1B in 2025, though profitability remains modest with a 1.96% net margin. Operating cash flow improved significantly to $1.0B in 2025, indicating stronger business execution.
The outlook remains positive with 77% analyst buy ratings and a $227.64 consensus price target representing 16% upside. Key opportunities include AI-powered communication growth and margin expansion, while risks center on high valuation multiples (P/E 311) and competitive pressures. The upcoming earnings report will be critical for validating the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
